Jacqueline Garcia, MD, Dana-Farber Cancer Institute, Boston, MA, talks on the impact of mutation screening on transplant decisions in myelodysplastic syndromes (MDS). The presence of certain mutations at the time of transplantation are known to predict poor prognosis. Dr Garcia comments that with increasing understanding of disease biology, it is becoming more clear that different mutations must be tackled in different ways and should play a role in decision making. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.